MedPath

European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)

Phase 2
Terminated
Conditions
PAD
Infrapopliteal Lesions
Interventions
Device: Cotavance Paclitaxel Coated Balloon
Device: Standard balloon angioplasty
Registration Number
NCT01260870
Lead Sponsor
Bayer
Brief Summary

To evaluate the procedural safety and to identify and characterize therapeutic and functional endpoint assessments in subjects with documented critical limb ischemia who received treatment with the Cotavance Paclitaxel-Coated Balloon vs. those who received POBA only.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Subjects with CLI
Read More
Exclusion Criteria
  • Participation in another research trial
  • Medical conditions the study doctor will assess
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CotavanceCotavance Paclitaxel Coated Balloon-
Standard balloon angioplastyStandard balloon angioplastyPOBA
Primary Outcome Measures
NameTimeMethod
Evaluate procedural safety30 days
Secondary Outcome Measures
NameTimeMethod
Identify and characterize therapeutic and functional endpoint assessments5 years

Trial Locations

Locations (4)

Medical University

🇦🇹

Graz, Austria

AZ St.-Blasius Hospital

🇧🇪

Dendermonde, Belgium

University Hospital

🇨🇭

Zurich, Switzerland

St. George's Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath